TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia

Abstract Pediatric acute myeloid leukemia (AML) is a poor prognostic subtype of pediatric leukemia. However, the detailed characteristics of many genetic abnormalities are yet to be established in this disease. Although TP53 and RB1 are established as representative tumor suppressor genes in various cancers, alterations of these two genes, especially RB1 , have not been characterized in pediatric AML. We performed next‐generation sequencing in 328 pediatric AML patients from the Japanese AML‐05 trial to ascertain TP53 and RB1 alterations, and their prognostic implications. We identified seven patients with TP53 alterations (2.1%) and six patients with RB1 alterations (1.8%). These alterations were found in only patients without RUNX1::RUNX1T1 , CBFB::MYH11 , or KMT2A rearrangements. TP53 and RB1 were frequently co‐deleted with their neighboring genes PRPF8 and ELF1 , respectively. Patients with TP53 alterations had significantly lower 5‐year overall survival (OS; 14.3% vs. 71.4%, p < 0.001) and lower 5‐year event‐free survival (EFS; 0% vs. 56.3%, p < 0.001); similarly, patients with RB1 had significantly lower 5‐year OS (0% vs. 71.8%, p < 0.001) and lower 5‐year EFS (0% vs. 56.0%, p < 0.001) when compared to patients without these alterations. In gene expression analyses, oxidative phosphorylation, glycolysis, and protein secretion were upregulated in patients with TP53 and/or RB1 alterations. Additionally, Kaplan–Meier analysis revealed that high expressions of SLC2A5 , KCNAB2 , and CD300LF were related to poor OS of non‐core‐binding factor AML patients ( p < 0.001, p = 0.001, and p = 0.021, respectively). This study will contribute to the development of risk‐stratified therapy and precision medicine in pediatric AML.